April 9, 2021
Daiichi Sankyo said on April 7 that the first patient has been dosed in a first-in-human PI/II study for its menin inhibitor DS-1594 in adults with relapsed/refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It has been reported...read more